TYRA-300 0.125 mg/kg + TYRA-300 0.25 mg/kg + TYRA-300 0.375 mg/kg + TYRA-300 0.50 mg/kg
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Mar 4, 2025 → Jun 1, 2030
NCT ID
NCT06842355About TYRA-300 0.125 mg/kg + TYRA-300 0.25 mg/kg + TYRA-300 0.375 mg/kg + TYRA-300 0.50 mg/kg
TYRA-300 0.125 mg/kg + TYRA-300 0.25 mg/kg + TYRA-300 0.375 mg/kg + TYRA-300 0.50 mg/kg is a phase 2 stage product being developed by Tyra Biosciences for Achondroplasia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06842355. Target conditions include Achondroplasia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06842355 | Phase 2 | Recruiting |
Competing Products
20 competing products in Achondroplasia
Other Products from Tyra Biosciences
TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBDPhase 2
47
Dabogratinib (TYRA-300) 60mg + Dabogratinib (TYRA-300) 80mg + Dabogratinib (TYRA-300) TBDPhase 2
47
TYRA-300Phase 1/2
36
TYRA-430Phase 1
28
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles + Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cyclesPhase 1
28